** Shares of Lucid Diagnostics LUCD.O down 24.2% to $1.25 before the bell after overnight follow-on priced
** New York-based commercial-stage co late Weds sold 12.5 mln shares at $1.20 for $15 mln gross proceeds
** Offering priced at 27.3% discount to last sale
** The subsidiary of PAVmed Inc PAVM.O plans to use net proceeds for working capital, general purposes
** LUCD had ~90.75 mln shares outstanding as of Mar 20, per most recent 10-k filing, giving it $150 mln market cap
** Co's flagship product, the EsoGuard Esophageal DNA Test, is used to screen for esophageal precancer and cancer in at-risk gastroesophageal reflux disease (GERD) patients
** Stock ended 2024 at 82 cents
** Canaccord Genuity sole bookrunner for stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.